Australia's most trusted
source of pharma news
Posted 27 May 2025 AM
Just days after approving AstraZeneca’s Datroway, the TGA has hinted that the company’s next breast cancer treatment could arrive by early next year.
An update to the regulator’s prescription medicine determinations and designations list shows that camizestrant was granted the priority review pathway on 5 May for use in combination with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during first line endocrine-based therapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.